G-protein-coupled glucocorticoid receptors on the pituitary cell membrane. (1/7)
Rapid, nongenomic actions of glucocorticoids (GCs) have been well documented, but information about putative membrane receptors that mediate them is scarce. We used fluorescence correlation spectroscopy to search for membrane GC-binding on the mouse pituitary cell line AtT-20. A slowly diffusing fraction (tau3; diffusion constant 3x10(-10) cm2 s-1) of fluorescein-labeled dexamethasone on the cell membrane corresponds to fluorescein-dexamethasone binding. Preincubation experiments were performed to test binding specificity: a 500-fold excess of unlabeled dexamethasone abolished subsequent fluorescein-dexamethasone membrane binding from 58+/-2 (control) to 8+/-1 (% of tau3, mean+/-s.e.m.), the natural ligand corticosterone prevented it partially (29+/-2), while the sex steroids estradiol (56+/-4) and progesterone (50+/-4) and the GC-receptor antagonist RU486 (56+/-2) had no effect. Preincubation with pertussis toxin resulted in disappearance of the slowest diffusion component (11+/-4) suggesting association of the receptor with a G-protein. Varying the concentration of fluorescein-dexamethasone showed that membrane binding is highly cooperative with an apparent Kd of 180 nM and Bmax of 230 nM. Taken together, these results demonstrate high-affinity GC-binding on the cell membrane of AtT-20 cells with characteristics distinct from intracellular binding. (+info)Flumethason-induced calving is preceded by a period of myometrial inhibition during luteolysis. (2/7)
The temporal relationship among changes of the concentrations of the 13,14-dihydro-15-keto metabolite of prostaglandin F2 alpha (PGFM), estrone (E1) and estrone sulphate (E1S) in maternal arterial plasma (MP) and amniotic fluid (AF), the prepartum progesterone (P4) decline in MP, and the evolution of uterine electromyographic (EMG) activity was investigated in 6 cows. Calving was induced by a single i.m. injection of 5 mg flumethason on Day 270 of gestation. The period under investigation was subdivided into four consecutive periods: Period 1 covered the last 2 days before flumethason treatment; Period 2 (mean +/- SEM duration: 16.1 +/- 2.5 h), Period 3 (8.8 +/- 1.1 h), and Period 4 (13.0 +/- 1.5 h) together included the interval between injection and the onset of the expulsive stage of induced parturition. Each was defined by its pattern of uterine EMG activity. During Periods 1 and 2, this activity occurred in long episodes (2-20 min; contractures) at a similar mean (+/- SEM) frequency (0.51 +/- 0.14/h and 0.42 +/- 0.07/h, respectively). No significant differences in hormonal concentrations in MP and AF between these two periods were detected. During Period 3, contractures nearly disappeared (freq: 0.09 +/- 0.05/h), and in MP mean P4 levels were significantly lower and PGFM levels were significantly higher than before. Mean PGFM concentrations in AF were not significantly changed during Period 3. Finally, during Period 4, EMG activity reappeared and a parturient EMG pattern gradually evolved in the presence of a further significant decline of P4 levels and significant increase of PGFM concentrations in MP.(ABSTRACT TRUNCATED AT 250 WORDS) (+info)Effects of induced parturition and early obstetrical assistance in beef cattle. (3/7)
Pregnant crossbred beef females (33 second-calf cows and 73 primiparous heifers) bred to a single Hereford sire were assigned to a 2(3) factorial study involving age of dam, natural (NP) or induced (IP) parturition and late emergency (LA) or forced early (EA) obstetrical assistance. Parturition was induced with 10 mg flumethazone given i.m. between 1400 and 1600 on d 272 of gestation; EA was given when the cervix and birth canal were fully dilated. Average IP occurred 39.6 h postinjection, and 95.3% of the treated dams responded within 60 h postinjection; gestation was shortened 2.9 d (P approximately equal to .07). Dystocia score (from 1 = no assist to 4 = major traction required and 5 = abnormal presentation) was 1.12 vs 2.40 for LA and EA, respectively (P less than .01), and 11% of LA vs 84% of EA were assisted. Calf vigor score (1 = normal to 3 = severely depressed or dying) at birth was 1.3 for NP and 1.1 for IP (P approximately equal to .06) and 1.3 for EA and 1.1 for LA (P less than .05). This effect of EA was due to reduced vigor of calves experiencing abnormal presentation. Birth weights (BW) and weaning weights (WW) of calves from cows exceeded those from heifers (32.6 vs 30.8 kg, P less than .05; 210.9 vs 156.3 kg, P less than .01, respectively). Differences due to IP and EA in BW, WW, postpartum interval and conception rate were not significant, but weight gain of calves from EA dams tended (P approximately equal to .09) to be greater than weight gain of calves from LA dams.(ABSTRACT TRUNCATED AT 250 WORDS) (+info)Effects of adrenalectomy and glucocorticoids on puberty in gilts reared in confinement. (4/7)
The effect of adrenal function and flumethasone (FM, a synthetic glucocorticoid) on induction of puberty in crossbred gilts raised in confinement was examined in two experiments. In Exp. 1, gilts were adrenalectomized (Adx) or subjected to sham adrenalectomy (Sham) between 140 and 160 d of age. Twenty days later indwelling jugular catheters were implanted in Adx, Sham and another group of intact gilts designated as Controls, and the gilts were moved from confinement to outdoor pens and checked daily for estrus with a mature boar. Fewer (P less than .05) Adx (1/11) than Sham (9/14) gilts showed estrus and ovulated by 205 d of age. Response of Control gilts (6/14) was not different from the other groups. Although Adx gilts received 40 mg cortisone acetate and 10 mg deoxycorticosterone acetate daily throughout the experiment, mean plasma glucocorticoids were lower (P less than .05) in Adx (24 +/- 4.7 ng/ml) than in either Sham (47 +/- 8.1 ng/ml) or Control (44 +/- 6.1 ng/ml) gilts. Experiment 2 was conducted to determine whether FM given to Adx gilts immediately after surgery could have inhibited estrus and ovulation. Intact gilts received a total of 27.5 (FM1) or 17.5 (FM2) mg FM over 4 d between 150 and 160 d of age before relocation and boar exposure 20 d later. Control gilts received no injections. Nine of 13 FM-treated but none of the Control gilts showed estrus. It is concluded from these results that the adrenal glands may facilitate the onset of puberty in gilts through increases in glucocorticoid production, but that this is not required for puberty to occur. (+info)Therapeutic utilization of the diurnal variation in pituitary-adrenocortical activity. (5/7)
The degree of pituitary-adrenocortical suppression resulting from exogenous corticosteroid is related to the time of day the steroid is administered. Morning administration has less effect and evening administration a greater effect than do divided doses given over the course of the day. Clinical studies have shown that in the great majority of patients with corticosteroid responsive diseases, an intermittent dosage schedule is at least as effective as is administration of an equal dose in a three or four times a day regimen. Other undesirable side effects of corticosteroid therapy may also be decreased by an intermittent schedule. It is suggested that the customary divided dosage schedule for corticosteroid administration be replaced with an intermittent regimen, the medication being given in the morning. This may be once a day, or, if therapeutic results are satisfactory, once every other day. (+info)Effect of day gestation on inductions of lambing with flumethasone. (6/7)
Three-hundred and sixty-nine ewes were examined for the effect of day of flumethasone injection on induction of parturition. Ewes were treated with either 2 mg flumethasone (FLU) or physiological saline (control) on days 138 through 144 of gestation as determined by date of marking by rams. Average time to lambing post-treatment was 86.7 +/- 8.0 hr for FLU-injected ewes and 155.9 +/- 7.9 hr for control ewes (P less than 0.1). Sixty-four percent of the FLU-injected ewes lambed within 72 hr after treatment, compared to 17% of the control ewes (P less than .01). The average interval to lambing for the FLU-treated ewes responding within 72 hr was 49.5 +/- 2.1 hours. FLU treatment on days 140 through 144 of gestation resulted in a shorter (P less than .05) interval from treatment to birth and more (P less than .01) ewes lambing within 72 hr after treatment than did treatment on days 138 and 139. (+info)Induction of parturition in the ewe. (7/7)
One-hundred and seventeen ewes were used in a study of induction of parturition. Ewes were treated with either 2 mg flumethasone (FLU), 15 mg prostaglandin F2 alpha-THAM salt (PGF) or physiological saline (control) on day 141 of gestation, as determined by dates of marking by rams. Eighty-nine percent of the ewes treated with FLU and 33% of the ewes treated with PGF lambed within 72 hr post-treatment. More (P less than .01) ewes treated with PGF or FLU lambed within 72 hr than did control ewes. The interval from treatment to parturition was shorter in FLU (P less than .01) and PGF (P less than .05) treated ewes than in ewes given saline. (+info)Fluticasone is a synthetic glucocorticoid medication that is commonly used as an anti-inflammatory agent in the treatment of various conditions such as asthma, allergies, and skin disorders. It works by binding to specific receptors in cells, which leads to a decrease in the production of inflammatory chemicals called cytokines. This helps to reduce swelling, redness, and itching associated with inflammation.
Fluticasone is available in various forms, including inhalers, nasal sprays, and creams or ointments. It is important to use fluticasone exactly as directed by a healthcare provider, as improper use can increase the risk of side effects such as thrush (a type of fungal infection) in the mouth or throat.
Some common brand names of fluticasone include Flonase (for nasal allergies), Advair and Ventura HFA (for asthma), and Cutivate (for skin conditions).
Flumetasone pivalate
Diflucortolone
Flumetasone
Cradle cap
List of MeSH codes (D04)
RPM - FLUMET - Kihorse Flumethasone: 0.5 mg PRESENTATION 10ml
RPM - FLUMET - First Horse Vet Care Flumethasone: 0.5 mg PRESENTATION 10ml
Flumetasone pivalate - Wikipedia
pharmaceutical ingredient Flumethasone CAS 2135-17-3-Wholesale,buy,sell,pharmaceutical ingredient Flumethasone CAS 2135-17...
Cost of Psoriasis Therapy: Considerations for Therapy Selections
Medword USP List of Prescription Drugs, Orphan Drugs, & OTC Pharmaceuticals: Letter F
Lexical Tools
Biomarkers Search
Légis Québec
C65151|Non-Small Cell Carcinoma|create|30-MAR-07|(null)|(null
Health Product InfoWatch - July 2022 - Canada.ca
Glentham Life Sciences - Steroids
National Ambulatory Medical Care Survey, 1994
Intertrigo | DrugBank Online
Code System Concept
Large-Scale Phenotype-Based Antiepileptic Drug Screening in a Zebrafish Model of Dravet Syndrome | eNeuro
MH DELETED MN ADDED MN
MeSH Browser
MeSH Browser
Bio2Vec
Nantong Chem-Tech.(Group) Co.,Ltd
DeCS
博拓化学 | 化学原料药及中间体生
I:docorrespsecretar ewdrugs e.pdf
Buy Cancer Drugs Online | Canadian Pharmacy | CancerDrugsCanada.net
February 2023 - MIRADUKES MAGNIFICENT SOLUTIONS
E0000163|Adriamycin|doxorubicin
Dexamethasone Sodium Phosphate Latest Price, Dexamethasone Sodium Phosphate Manufacturer,Exporter
Pivalate 0.021
- 로카살렌 연고 flumethasone pivalate 0.02%, salicylic acid 3%, 전문의약품은 중등도의 스테로이드이며 스테로이드는 남용시 잠행성 진균증 을 유발할 수 있습니다. (openwiki.kr)
Clioquinol2
- This combination product contains two medications: clioquinol and flumethasone. (rxhealthmed.ca)
- This medication contains 2 active ingredients: clioquinol and flumethasone. (rxhealthmed.ca)
Corticosteroid3
- Bimasone Injectable Solution is a corticosteroid drug that contains flumethasone in the same concentration and dosage form as Flucort. (dvm360.com)
- Flumethasone is a potent corticosteroid. (horseracingreform.com)
- The warnings issued for the flumethasone, a corticosteroid, findings do not make sense because flumethasone is not a threshold substance and is not on the National Uniform Medication Program (NUMP) list so a finding at any concentration should have been a violation. (horseracingreform.com)
Fluticasone Propionate1
- In US2002/0133032 Abbott claim a process towards fluticasone propionate starting from flumethasone. (allindianpatents.com)
Concentration1
- The commission's records show that the horse in question had a flumethasone concentration of 95.4 picograms per milliliter (pg/ml). (horseracingreform.com)
Grade1
- Abbott also claims that a 6a-chloro-9a-fluoro-impurity present in commercial grade flumethasone necessitates an elaborate purification of flumethasone prior to use. (allindianpatents.com)
Drugs3
- Unlike most of the laboratory findings provided to me by the Pennsylvania Department of Agriculture (PDA) for other drugs, concentrations of flumethasone were not reported for any of these six findings. (horseracingreform.com)
- Flumethasone falls in the category of most drugs and other substances that equine testing laboratories across the nation encounter - those that are not approved for therapeutic uses and have no threshold. (horseracingreform.com)
- This leads to the most important question: With more than 1000 similar non-threshold drugs out there, are there any other findings by PETRL, for drugs other than flumethasone, that have been detected in testing but have gone unprosecuted? (horseracingreform.com)
Pivalate1
- Flumethasone pivalate (Locorten). (wikipedia.org)